RESEARCH





Association between nutritional status scores and the 30-day mortality in patients with acute kidney injury: an analysis of MIMIC-III database

Tingting Gao¹ and Xueyuan Yu^{2*}

Abstract

Background Studies have proven that the risk of acute kidney injury (AKI) increased in patients with malnutrition. Prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) were general tools to predict the risk of mortality, but the prognostic value of them for in-hospital mortality among patients with AKI have not been validated yet. Herein, this study aims to explore the association between PNI and GNRI and 30-day mortality in patients with AKI.

Methods Demographic and clinical data of 863 adult patients with AKI were extracted from the Medical Information Mart for Intensive Care III (MIMIC-III) database in 2001–2012 in this retrospective cohort study. Univariate and multivariate Cox proportional regression analyses were used to explore the association between PNI and GNRI and 30-day mortality. The evaluation indexes were hazard ratios (HRs) and 95% confidence intervals (CIs). Subgroup analyses of age, Sequential Organ Failure Assessment (SOFA) score and Simplified Acute Physiology (SAPS-II) score were also performed.

Results Totally, 222 (26.71%) patients died within 30 days. After adjusting for covariates, PNI \geq 28.5 [HR=0.71, 95%CI: (0.51–0.98)] and GNRI \geq 83.25 [HR=0.63, 95%CI: (0.47–0.86)] were both associated with low risk of 30-day mortality. These relationships were also found in patients who aged \geq 65 years old. Differently, high PNI level was associated with low risk of 30-day mortality among patients with SOFA score < 6 or SAPS-II score < 43, while high GNRI was associated with low risk of 30-day mortality among those who with SOFA score \geq 6 or SAPS-II score \geq 43 (all *P*<0.05).

Conclusion PNI and GNRI may be potential predictors of 30-day mortality in patients with AKI. Whether the PNI is more recommended for patients with mild AKI, while GNRI for those with severe AKI is needed further exploration.

Keywords AKI, PNI, GNRI, SOFA, SAPS-II, 30-day mortality, MIMIC-III

*Correspondence:

Xueyuan Yu

snowyuyu@outlook.com

¹Department of Comprehensive Medical, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan 030032, Shanxi, P.R. China ²Department of Nephrology, Qi Lu Hospital of Shandong University, No.107 Wenhua west road, Lixia District, Jinan 250012, Shandong, P.R. China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Acute kidney injury (AKI) is defined by a sudden dysfunction of the kidney, and the in-hospital mortality of AKI is as high as 50% overall [1, 2]. AKI is related to adverse metabolic and nutritional outcomes such as metabolic abnormalities of protein and fat, inducing proinflammatory state and immune ability impairment [3]. The possible effects of nutritional conditions, substrate balance, and treatment processes cannot be neglected in hospitalization of patients with AKI [4].

The risk of AKI increased in patients with malnutrition [5]. Studies have showed that malnutrition in old patients with AKI was associated with high risk of inhospital mortality [6, 7]. Therefore, assessment of nutritional status is essential for the identification of patients with AKI who have high risk of mortality. Among various nutritional assessment tools, prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) have been reported to be associated with contrast-induced acute AKI [6, 8]. PNI is often used to evaluate postoperative outcomes and nutritional status in patients with malignancies [9], heart [10], kidney [11], and pulmonary [12] diseases. At the same time, GNRI is a general tool for predicting the risk of morbidity and mortality in elderly cancer patients [13]. Previous studies indicated that lower level of GNRI was associated with longer hospital stays, complications, and long-term mortality [14, 15]. However, the predictive value of PNI and GNRI of in-hospital mortality in patient with AKI have not been validated vet.

Herein, this study aims to explore the association between the PNI and GNRI and 30-day mortality in patients with AKI, and assess the predictive performance of them. We hope this study could provide some references for choosing optimal criteria for evaluation of the AKI prognosis, and to assist the clinical monitoring and treatment of AKI.

Methods

Study design and participants

Data of participants in this retrospective cohort study were extracted from the Medical Information Mart for Intensive Care III (MIMIC-III) database. The MIMIC-III was published by the computational physiology laboratory of Massachu-setts Institute of Technology (MIT, Cambridge, MA, USA), Beth Israel Deaconess Medical Center (BIDMC, Boston, MA, USA), and Philips Medical jointly. The clinical diagnosis and treatment information on more than 40,000 real patients who are predominantly White people living in the intensive care unit (ICU) of the BIDMC were collected and sorted out by MIMIC database since 2001. The publicly data are available on the website: https://mimic.mit.edu/. A total of 863 adult patients with AKI, and hospitalized in the ICU at first admission for more than 1 day were initially included. Patients without the information of PNI, GNRI, oxygen saturation (SpO₂), neutrophil lymphocyte ratio (NLR), or prothrombin time (PT) were excluded. Finally, 831 of them were eligible. Due to the MIMIC-III database was publicly available, and the written informed consent from participants has been obtained before the survey, no ethical approval of the Institutional Review Board (IRB) of Qi Lu Hospital of Shandong University was needed. Besides, all the study methods were performed in accordance with the relevant guidelines and regulations.

Diagnosis of AKI

AKI diagnosis was according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines [16]: serum creatinine (Scr) increased by \geq 0.3 mg/dL within 48 hours, or increased to \geq 1.5 fold from baseline within the prior 7 days, or urine volume<0.5 mL/kg/h for 6 hours or more.

Definitions of PNI and GNRI

PNI was calculated by the method postulated by Onodera et al. [17]: $[10 \times \text{albumin (gr/dL)}] + [0.005 \times \text{absolute preoperative lymphocyte count (per mm³)}]$. We obtained the optimum cut-off PNI value of 28.5 using the X-tile software [18], and then divided the PNI into two levels: PNI < 28.5 and PNI ≥ 28.5.

GNRI is an objective screening tool developed by Bouillanne et al. [19] to predict the nutrition-related complications in older persons. GNRI was calculated by the following formula: GNRI = $[1.489 \times \text{serum albu-}$ min (g/L)] + $[41.7 \times (\text{current weight in kilograms/ideal}$ weight)]. Ideal weight was calculated using the Lorentz formulas [19]: height (cm)-100- ([height (cm) -150] /4) for men and height (cm)-100- ([height (cm)-150] /2.5) for women. When current weight exceeded ideal body weight, we set current weight in kilograms/ideal weight=1. In addition, we classified GNRI into four levels according to the nutritional conditions: absent malnutrition (≥ 100), mild (97.50-99.99), moderate (83.50-97.49) and severe (<83.50) malnutrition [20].

Variables collection

The study variables were collected within the first 24 hours after ICU admission, including age, gender, race, mechanical ventilation use, vasopressors use, renal replacement therapy, AKI stage, ICU length of stay, Charlson comorbidity index (CCI), Sequential Organ Failure Assessment (SOFA) score, Simplified Acute Physiology Score II (SAPS-II), Glasgow Coma Scale (GCS), hemoglobin (HB), red blood cell distribution width (RDW), anion gap (AG), esti mated glomerularfiltrationrate (eGFR), SpO₂, NLR, PT, lymphocytes count, neutrophil count, platelet count, blood glucose, international normalized ratio (INR), respiratory rate (RR), height, weight, and body mass index (BMI).

The BMI was calculated as the weight in kilograms divided by the square of the height in meters and was categorized into normal (18.5–25.0 kg/m²), overweight (25.0-29.9 kg/m²), obesity (\geq 30 kg/m²), and underweight (<18.5 kg/m²). The eGFR was calculated according to CKD-EPI (mL/min/1.73m²) equation. NLR (neutrophil-lymphocyte ratio)=neutrophil count/ lymphocytes count.

Outcome and follow-up

The study outcome was 30-day mortality. The MIMIC-III followed up patients' survival status by information in the electronic medical charts and hospital department records, or making contact with the patients, their family members, their attending health care workers, or family physicians on the phone. The follow-up ended until patients died or 30 days after the ICU admission.

Statistical analysis

We used the Kolmogorov-Smirnov test to test the normality of quantitative data. Normal distributed data were described by mean±standard error (mean±SE), and independent-samples t test for comparation between groups. Skewed distribution data were described by median and quartiles [M (Q1, Q3)], and Mann-Whitney U rank sum test was used for comparation. Frequency and composition ratio [N (%)] was used to describe the distribution of categorical data, and chi-square test (χ^2) was used for cooperation.

We used the Spearman rank correlation analyses to assess the associations between PNI, GNRI, and eGFR, AKI stage, SOFA score, and SAPS-II score respectively. Univariate Cox regression model was used to screen the covariates. Univariate and multivariate Cox regression models were established to explore the relationships between PNI and GNRI and 30-day mortality in patients with AKI. Model 1 was the crude model. Model 2 adjusted for the sociodemographic variables including age, gender, and race. Model 3 additionally adjusted for mechanical ventilation use, vasopressors use, AKI stage, ICU length of stay, CCI, SOFA, SAPS-II, HB, RDW, AG, eGFR, SpO₂, NLR, PT, GCS, INR, and RR basing on the Model 2. We also explored these associations in age (<65years old and \geq 65 years old), SOFA (<6 and \geq 6) and SAPS-II (<43 and \geq 43) subgroups. The predictive performances of PNI and GNRI on 30-day mortality patients with AKI was assessed by Kaplan-Meierwith (KM) curve and C index.

The evaluation indexes were r_s , hazard ratios (HRs) and 95% confidence intervals (CIs). Two-sided P<0.05

is considered significant. Missing variables were deleted and the sensitivity analysis of characteristics of participants before and after deletion of missing data was showed in Table S1. Statistical analyses were by SAS 9.4 (SAS Institute., Cary, NC, USA).

Results

Characteristics of participants

Figure 1 was the flowchart of participants screening. A total of 863 adult AKI patients with information of PNI and GNRI, and were hospitalized in the ICU over 1 day at the first admission were initially included. Then we excluded patients without information of SpO_2 (n=3), NLR (n=1) or PT (n=28). Finally, 831 of them were eligible.

Table 1 was the characteristics of AKI patients. Among the participants, 222 (26.71%) died within 30 days. The average age of patients was 64.61 years old, and 431 (51.87%) of them aged \geq 65 years old. The median length of ICU stay was 4.25 days. Most of the patients had a PIN \geq 28.5 (76.90%) and a GNRI \geq 83.25 (57.52%). In addition, between survival group and 30-day mortality group, age, race, mechanical ventilation use, vasopressors use, AKI stage, CCI, SOFA, SAPS-II, HB, RDW, AG, eGFR, SpO₂, NLR, PT, GCS, INR, RR, lymphocytes, follow-up time, PNI and GNRI of the patients were significantly different (all *P*<0.05).

Correlation between PNI and GNRI and severity of AKI

We used eGFR, AKI stage, SOFA score and SAPS-II score to reflect the severity of AKI, and Table 2 showed the correlation between PNI and GNRI and the severity of AKI. The results showed that AKI stage (r_s =-0.198), SOFA score (r_s =-0.310) and SAPS-II score (r_s =-0.276) were all negatively associated with PNI, while eGFR (r_s =0.076) had a positive relationship. AKI stage (r_s =-0.200), SOFA score (r_s =-0.320) and SAPS-II score (r_s =-0.300) were also negatively associated with GNRI.

Relationships between PNI and GNRI and 30-day mortality

Table S2 showed the covariates associated with 30-day mortality. After adjusting for the covariates, comparing to low PNI and GNRI levels, AKI patients who had high PNI [HR=0.71, 95%CI: (0.51-0.698)] and GNRI [HR=0.63, 95%CI: (0.47-0.86)] levels were seemed to have lower risk of 30-day mortality (Table 3).

We then explored these associations in subgroups of age, SOFA score, and SAPS-II score (Table 3). Among patients aged \geq 65 years old, these negative relationships were also significant (all *P*<0.05). In patients with SOFA score < 6 [HR=0.38, 95%CI: (0.18–0.81)] or SAPS-II score <43 [HR=0.22, 95%CI: (0.11–0.46)], high PNI was associated with low risk of 30-day mortality, while in those who with SOFA score \geq 6 [HR=0.65, 95%CI:



Fig. 1 Flow chart of the participants screening

(0.46-0.93)] or SAPS-II score ≥ 43 [HR=0.63, 95%CI: (0.44-0.88)], high GNRI was associated with low risk of 30-day mortality.

The predictive performances of PNI and GNRI on 30-day mortality

Figures 2 and 3 were respectively the KM curve of associations between PNI level and GNRI level and the survival probability in patients with AKI. The results showed that lower PNI and GNRI were both associated with a lower survival possibility (all P<0.0001). Table 4 showed the C-index of PNI and GNRI on 30-day mortality, and the results indicated that PNI (C-index=0.807) and GNRI (C-index=0.806) may be potential predictors for 30-day mortality in patients with AKI.

Discussion

This study explored the relationships between PNI and GNRI and 30-day mortality in patients with AKI. Our results showed that high levels of PNI and GNRI were both associated with low risk of 30-day mortality. These relationships were also found in patients who aged \geq 65 years old, with different SOFA scores and SAPS-II scores. Furthermore, it seemed that PNI and GNRI may be potential predictors for AKI in-hospital mortality.

To our knowledge, few studies have reported the predictive value of PNI for AKI prognosis. A pilot study by Shimoyama et al. [21] showed that PNI was a predictor of septic AKI prognosis. Hu et al. [22] suggested that the PNI may be a good predictor for identification of patients at high risk of AKI and mortality in the coronary care unit (CCU). PNI has been found as an independent risk factor for contrast-induced acute kidney injury (CI-AKI) [23], and was inversely and significantly associated with the development of CI-AKI in ST-elevation myocardial infarction (STEMI) [24]. Our research found that PNI≥28.5 was significantly associated with low risk of 30-day mortality in patients with AKI, which may complement relevant research to a certain extent. Pathophysiological mechanisms of the relationship between high PNI and 30-day mortality in AKI have not been completely understood, and proinflammatory state may be a possible explanation. Inflammation was associated with increased catabolism and decreased albumin synthesis, and hypoalbuminemia may increase blood viscosity and disrupt endothelial function [25, 26]. Low lymphocyte count may be linked to increased inflammatory activity and pre-existing immunosuppression [27]. Therefore, the PNI basing on combination of serum albumin level and the lymphocyte count may be able to estimate

Table 1 Characteristics of AKI patients

Value Value juin (Value) (m + 3 m) (m	Variables	Total	Survival	Mortality	Statistics	D
Age, yang, Neam-SDAds 1=150963.55±67.5257.520.020Age yang, Neam-SDAge velocity, Neam302 (50.57)92 (41.44)9.000Age velocity, Neam431 (51.87)301 (94.3)130 (65.50)9.2Age velocity, Neam431 (61.87)265 (45.51)83 (57.39)9.20.002Amale483 (81.82)245 (65.49)130 (62.51)9.20.002Amale483 (81.21)245 (65.49)130 (62.51)9.20.002Amale483 (81.21)437 (70.0)130 (62.51)9.20.002Amale12 (1.47)10 (1.64)7.0 (80.50)1.11.9Male483 (60.22)112 (12.75)6.1 (2.73)1.11.9Black24 (63.51)132 (26.47)1.9 (2.81)1.91.0Male26 (2.51)32 (45.37)1.92 (84.77)1.91.1No416 (2.000126 (45.17)1.0 (2.81)1.91.1No416 (2.00012.6 (45.17)1.0 (2.81)1.91.1No416 (2.00012.0 (2.63)1.1 (2.9)1.11.1No416 (2.00012.0 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)No416 (2.00012.0 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)No416 (2.00012.0 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)1.1 (2.9)No416 (2.00012.0 (2.9)		(n=831)	(n=609)	(n = 222)	Statistics	P
Age groups n (%)	Age, years, Mean \pm SD	64.61 ± 15.99	63.55 ± 16.18	67.52 ± 15.10	t=-3.19	0.001
App < c6 401 (81.3) 308 (50.57) 92 (1/4) Gender, n (%) x² = 25.1 0.113 Fornale 348 (41.88) 265 (43.51) 83 (37.30) Male 483 (81.21) 346 (66-49) 139 (62.51) Male 483 (81.21) 445 (66-49) 139 (62.51) Stan 12 (1.40) 10 (1.64) 20.900 White 56 (68.31) 437 (71.76) 139 (62.51) Black 21 (2.53) 17 (2.79) 4 (1.80) - Others 16 (20.22) 17 (2.79) 4 (1.80) - Others 270 (52.49) 217 (53.63) 53 (23.77) - No 216 (50.50) 346 (66.11) 70 (1.53) - Ves 15 (49.42) 236 (33.19) 15 (2.64.77) - No 416 (50.05) 346 (56.51) 71 (1.53) - - No 807 (7.11) 588 (60.57) 19 (82.56) - - No 14 (45 (1.74.5) 12 (62.05) 11 (2.27.73) Z=1.7	Age groups, n (%)				$\chi^2 = 5.44$	0.020
Age.265 301 (91.47) 301 (91.47) 303 (93.59) Fernale 346 (1.48) 265 (35.51) 83 (73.59)	Age < 65	400 (48.13)	308 (50.57)	92 (41.44)		
Cender, n(%) ···· ·k ² =2.51 0.113 Male 483 (81.2) 264 (43.5) 83 (37.2) ···· ···· Race, n(%) ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ····· ···· ····	Age≥65	431 (51.87)	301 (49.43)	130 (58.56)		
Fermine 344 (41.80) 265 (43.51) 83 (73.9) Made 483 (81.2) 344 (66.40) 139 (62.61) Race, n (%) x x ¹ =17.05 0.002 Asian 121 (1.44) 101 (1.64) 139 (62.61) x Black 54 (66.93) 44 / (1.7c) 139 (62.61) x Black 54 (66.93) 44 / (1.7c) 139 (62.61) x Others 168 (20.22) 102 (16.75) 66 (29.73) x No 203 (23.49) 217 (35.63) 53 (23.67) x Ves 61 (67.51) 392 (64.37) 152 (66.47) x No 416 (50.06) 346 (56.81) 70 (31.53) x Ves 41.61 (39.94) 213 (34.5) 219 (98.65) x x Rolar topic x x ² = 25.5 0.110 No 416 (50.05) 319 (98.05) 19 (98.65) 19 (98.65) I 370 (42.89) 21 (34.5) 300 (20.75.00) 25 (23.73) x II	Gender, n (%)				$\chi^2 = 2.51$	0.113
Male483 (58.12)344 (56.49)139 (62.61)Bace, n (%)Bace, n (%)Whe570 (09.31)437 (17.70)199 (62.01)Whe570 (09.31)437 (17.70)199 (62.01)Block54 (65.01)437 (17.70)199 (62.01)Hippanic21 (23.3)17.27.9040.800Others168 (20.22)102 (16.75)65 (23.73)Mechanical wenthation use, n (%) </td <td>Female</td> <td>348 (41.88)</td> <td>265 (43.51)</td> <td>83 (37.39)</td> <td></td> <td></td>	Female	348 (41.88)	265 (43.51)	83 (37.39)		
Bace, n(b) VI.4 10 (16 64) 20000 Virtual Vi	Male	483 (58.12)	344 (56.49)	139 (62.61)		
Asin 12 (1.4) 10 (1.6) 2 (0.90) White 576 (69.3) 437 (71.70) 139 (62.01) 1 Black 54 (6.50) 437 (70.70) 139 (62.01) 1 Hispanic 12 (2.53) 17 (2.79) 4 (1.80)	Race, n (%)				$\chi^2 = 17.06$	0.002
Whe 576 (69.3) 437 (7.76) 139 (62.61) Black 54 (65.0) 43 (7.06) 11 (4.95) Hspanic 12 (2.33) 17 (2.79) 41 (180 Others 0.80 227 (32.49) 217 (35.63) 53 (23.87) Wes 56 (67.51) 30 2 (64.37) 169 (76.13) 2 Vacopressors use, n (%) x²=41.60 < 0.001 Vasopressors use, n (%) x²=2.55 0.110 No 0.67 (67.11) 588 (65.81) 70 (31.53) 2 No 0.67 (67.11) 588 (66.51) 10 (06.65) 2 No 0.67 (67.11) 588 (66.51) 10 (08.65) 2 2 No 0.67 (67.11) 588 (66.51) 10 (08.65) 2 2 2 0.001 No 0.67 (67.11) 588 (66.51) 10 (08.65) 2 2 2 0.001 No 0.67 (64.22) 0.30 (00.00.00 0.00 (00.00.00 0.00 (00.00.00 2 2 2.62 (0.001 Stat state 0.00 (00.	Asian	12 (1.44)	10 (1.64)	2 (0.90)		
Black 54 (6.50) 43 (7.06) 11 (4.95) Hispanic 21 (2.53) 7 (2.79) 4 (1.80) Orthers 168 (20.22) 102 (16.75) 65 (20.73) We chanical ventilation use, n (%) $\chi^2 = 10.26$ 0.001 No 250 (32.49) 120 (15.75) 320 (64.37) 169 (76.13) Vers 561 (67.51) 320 (64.37) 169 (76.13) $\chi^2 = 10.26$ $\sqrt{0.01}$ Vers 416 (50.06) 364 (56.81) 152 (08.47) $\chi^2 = 2.55$ 0.110 No 416 (28.90.4) 263 (84.19) 152 (08.47) $\chi^2 = 2.55$ 0.101 Ne 807 (97.11) 588 (96.55) 19 (98.65) $\chi^2 = 2.55$ 0.101 Ne 307 (44.52) 308 (50.57) 219 (98.65) $\chi^2 = 8.42$ c.001 III 316 (63.31) 15 (12.74) 14 (16.51) 1101 136 (13.63) 15 (12.47) 14 (14.51) ICU length of stay, day, M(Q_1, Q_2) 420 (10.04.00) 200 (10.00,000) 200 (10.00,000 200 (20.00,000) 200 (20.00,00) 200 (20.00,0	White	576 (69.31)	437 (71.76)	139 (62.61)		
Hispanic Others21 (2.53)17 (2.79)4 (1.80)Others168 (20.22)10 (21.675)66 (29.73)Mechanical ventilation use, n (%)270 (32.49)217 (35.63)53 (23.87)No270 (32.49)217 (35.63)160 (76.13)Vasopressors use, n (%) χ^2 =41.60<0001	Black	54 (6.50)	43 (7.06)	11 (4.95)		
Others I68 (20.2) I02 (16.75) 66 (29.73) Machanical ventilation use, n(%) 270 (32.49) 217 (35.63) 53 (23.87) Vaso 501 (67.51) 392 (64.37) 169 (76.13) Vaso 416 (20.06) 346 (56.81) 70 (31.53) Ves 415 (49.04) 263 (43.19) 152 (68.47) Renal replacement therapy, n(%) 72 (2.89) 21 (3.45) 31 (3.5) Ves 415 (17.45) 588 (60.55) 19 (86.66) 72 (-2.65) Ves 24 (2.89) 21 (3.45) 31 (3.5) 72 (-8.42) Ves 24 (2.89) 126 (20.69) 19 (85.66) 72 (-8.42) I 145 (17.45) 126 (20.69) 19 (85.66) 72 (-8.42) III 137 (24.23) 308 (03.7) 62 (27.93) Z-1.28 0.202 III 168 (30.3) 175 (22.7) 11 (16.35) 7-1.28 0.202 III 145 (17.45) 18 54 2.44 12 (23.7.93) Z-1.28 0.201 III 145 (17.45) 19 (0.00,000 600 (0	Hispanic	21 (2.53)	17 (2.79)	4 (1.80)		
Mechanical ventilation use, n (%) V7 Sin (23,23) Sin (23,37) Sin (23,37) No 0.001 322 (04.3) 32 (04.3) 10 (07.6).3) V No 416 (50.06) 346 (56.81) 70 (31.3) V V C0.001 No 416 (50.06) 346 (56.81) 70 (31.3) V V No Sin (23,67)	Others	168 (20.22)	102 (16.75)	66 (29.73)		
No 270 (32.49) 271 (35.63) 53 (23.87) Yes 50 (67.51) 392 (64.37) 169 (76.13) Yes 61 (50.00) 263 (31.19) 169 (76.13) No 416 (50.00) 263 (31.19) 70 (31.53) Yes 815 (42.99) 23 (31.19) 152 (68.71) No 807 (97.11) 588 (96.55) 21 9 (96.65) 71 (10.10) Yes 21 (2.89) 21 (3.45) 21 9 (96.65) 72 (-0.01) No 816 (36.03) 175 (28.74) 141 (63.51) 72 (-0.02) II 165 (13.03) 175 (28.74) 141 (63.51) 72 (-0.02) ICU length of stay, day, M (Q ₁₁ Q ₂) 202 (25.08.78) 2.62 (25.89.28) 3.00 (20.02,73.03) 2 = 1.28 0.020 SAPS-IL, M (Q ₁₁ Q ₂) 2.00 (10.04.00) 2.00 (10.04.00) 8.00 (50.011.00) 2 = 8.02 0.001 SAPS-IL, M (Q ₁₁ Q ₂) 3.05 (25.08.78) 3.06 (30.00.00) 8.00 (50.011.00) 2 = 1.06.3 0.001 SAPS-IL, M (Q ₁₁ Q ₂) 3.05 (25.12) 1.11 ± 2.24 1.05 ± 2.03 1 = 3.00	Mechanical ventilation use, n (%)				$\chi^2 = 10.26$	0.001
Yes 561 (67.51) 392 (64.37) 169 (76.13) Vasoper: χ^2 =41.60 0.001 No 416 (50.06) 346 (56.81) 70 (31.53) Yes 415 (49.94) 263 (43.19) 152 (68.47) Renal replacement therapy, n (%) χ^2 =2.55 0.110 No 807 (97.11) 588 (96.55) 219 (98.65) Yes 24 (2.89) 21 (3.45) 3 (1.35) All stage, n (%) 152 (20.69) 19 (6.56) 22 (2.93) II 370 (44.52) 308 (50.57) 62 (27.93) 2-1.28 0.202 CCI, M (Q,, Q,) 200 (10.04.00) 200 (10.04.01) 300 (20.05.00) 2-6.69 <0.001	No	270 (32.49)	217 (35.63)	53 (23.87)		
Vasopressors use, n (%) , x ² = 41.60 346 (56.81) 70 (31.53) No 415 (49.94) 263 (31.9) 152 (68.47) . . Renal replacement therapy, n (%) . x ² = 2.55 0.110 No 807 (97.11) 588 (96.55) 21 (98.65) <td>Yes</td> <td>561 (67.51)</td> <td>392 (64.37)</td> <td>169 (76.13)</td> <td></td> <td></td>	Yes	561 (67.51)	392 (64.37)	169 (76.13)		
No416 (50.06)346 (56.81)70 (31.53)Yes15 (49.94)263 (34.19)15 (68.47)Renal replacement therapy, n (%)807 (97.11)588 (96.55)219 (98.65)Yes24 (28)21 (3.45)31.03Akl stage, n (%) $\chi^2 = 34.21$ < 0.001I145 (17.45)126 (20.69)19 (8.56)II370 (44.52)308 (50.57)62 (27.93)III370 (44.52)308 (50.57)62 (27.93)III370 (44.52)300 (30.00,500)25.66< 0.002CC, M(Q, Q_3)2.90 (100,400)200 (100,4001)300 (20.00,500)Z = 1.28< 0.002SOFA, M(Q, Q_3)6.00 (30.00,500)300 (30.00,500)S = 1.063< 0.001GCS, Maan ± SD15.72.9513.85 ± 2.5412.82.37.64t = 3.80< 0.001GCS, Maan ± SD15.60 ± 4.7515.16 ± 4.3416.82 ± 5.34t = 4.03< 0.001GCW, Mean ± SD15.60 ± 4.7515.16 ± 4.3416.82 ± 5.54t = 4.03< 0.001GOS, Maan ± SD9.65 ± 4.359.65 ± 4.359.65 ± 4.36< 0.001SPO_5, M(Maan ± SD9.65 ± 4.369.66 ± 4.369.60 ± 4.42< 1.11 ± 0.24< 0.001SPO_5, M(M, Q, Q_3)13.60 ± 1.70.7114.60 (13.40.1690)15.16 ± 1.20.71t = .36< 0.001GCS, Maan ± SD9.65 ± 4.359.65 ± 4.369.65 ± 4.36< 0.001GUW, Mean ± SD9.65 ± 4.359.65 ± 4.369.65 ± 4.36< 0.001GUW, Mean ± SD9.65 (8.01.740)13	Vasopressors use, n (%)				$\chi^2 = 41.60$	< 0.001
Yes 45 (49.94) 263 (43.19) 152 (68.47) Renal replacement therapy, n (%) $\chi^2 = 2.55$ 0.110 No 580 (95.5) 219 (98.65) 3 (13) Yes 24 (2.89) 21 (3.65) 3 (13) AKI stage, n (%) $\chi^2 = 84.21$ < 0.001	No	416 (50.06)	346 (56.81)	70 (31.53)		
Renal replacement therapy, n (%) x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x	Yes	415 (49.94)	263 (43.19)	152 (68.47)		
NoB07 (97.11)588 (96.55)219 (98.65) $ZI (3.45)$ <t< td=""><td>Renal replacement therapy, n (%)</td><td></td><td></td><td></td><td>$\chi^2 = 2.55$</td><td>0.110</td></t<>	Renal replacement therapy, n (%)				$\chi^2 = 2.55$	0.110
Yes24 (2.89)21 (3.45)3 (1.35)AKI stage, n (%)1145 (17.45)126 (20.69)19 (85.6)I370 (44.52)308 (50.57)62 (27.93)III316 (38.03)175 (28.74)141 (63.51)ICU length of stay, day, M (Q ₁ , Q ₃)42.5 (2.5.8.7.8)4.26 (2.5.8.2.8)4.16 (2.2.3.7.93)Z=-1.2.80.202CC, M (Q ₁ , Q ₃)200 (1.0.0.4.00)2.00 (1.0.0.4.00)3.00 (50.0.00)Z=5.69<0.0.01	No	807 (97.11)	588 (96.55)	219 (98.65)		
AKI stage, n (%) $\chi^2 = 84.21$ < 0.001 I 145 (17.45) 126 (20.69) 19 (8.56) III 370 (44.52) 308 (50.57) 62 (27.93) III 316 (38.03) 175 (28.74) 141 (63.51) ICU length of stay, day, M (Q ₁ , Q ₂) 4.25 (25.08.78) 4.26 (25.89.28) 4.16 (2.23,7.93) Z=1.28 0.202 CC, M (Q ₁ , Q ₂) 6.00 (4.00,9.00) 6.00 (3.00.8.00) 8.00 (5.00.11.00) Z=8.03 <0.001	Yes	24 (2.89)	21 (3.45)	3 (1.35)		
$ \begin{array}{ccccc} 1 & 145 (17.45) & 126 (20.69) & 19 (8.56) \\ 11 & 370 (44.52) & 308 (50.57) & 62 (27.93) \\ 11 & 316 (38.03) & 175 (28.74) & 141 (63.51) \\ 12 & 16 (232,793) & Z=-1.28 & 0.202 \\ 22 & 0.01 (100,4.00) & 2.00 (1.00,4.00) & 3.00 (20.05.00) & Z=5.69 & <0.001 \\ 50 FA, M (Q_1, Q_2) & 2.00 (1.00,4.00) & 2.00 (1.00,4.00) & 3.00 (20.05.00) & Z=5.69 & <0.001 \\ 50 FA, M (Q_1, Q_2) & 6.00 (4.00,9.00) & 6.00 (3.00,8.00) & 8.00 (5.00,11.00) & Z=8.03 & <0.001 \\ 50 FA, M (Q_1, Q_2) & 4.30 (0 33.00,55.00) & 39.00 (30.00,50.00) & 53.00 (43.00,6600) & Z=10.63 & <0.001 \\ GCS, Mean \pm SD & 13.57 \pm 2.95 & 13.85 \pm 2.54 & 12.82 \pm 3.76 & t=3.80 & <0.001 \\ Rb, g/dL, Mean \pm SD & 15.64 \pm 2.32 & 15.18 \pm 2.09 & 16.24 \pm 2.71 & t=5.31 & <0.001 \\ RDW, %, Mean \pm SD & 15.64 \pm 4.75 & 15.16 \pm 4.34 & 16.82 \pm 5.54 & t=4.03 & <0.001 \\ eGFR, mL/min/1.73m2, M (Q_1, Q_2) & 66.81 (37.33,96.98) & 73.41 (42.16,100.45) & 51.00 (31.21,86.23) & Z=4.84 & <0.001 \\ eGFR, mL/min/1.73m2, M (Q_1, Q_2) & 9.66 (58.01,7.40) & 8.73 (525,15.30) & 11.03 (7.18,21.95) & Z=3.97 & <0.001 \\ PT, seconds, M (Q_1, Q_3) & 1.30 (1.20,1.70) & 1.46 (0 (13.40,16.90) & 16.15 (14.10.20.70) & Z=5.64 & <0.001 \\ NR, M (Q_1, Q_3) & 1.30 (1.20,1.70) & 1.30 (1.20,1.60) & 15.51 (1.30,22.00) & Z=5.93 & <0.001 \\ NR, M (Q_1, Q_3) & 0.37 t 64.0 & 20.99 \pm 6.41 & 21.14 \pm 6.34 & t=-2.08 & 0.038 \\ Height, cm, Mean \pm SD & 169.33 \pm 14.96 & 169.36 \pm 15.88 & 169.24 \pm 12.13 & t=0.11 & 0.912 \\ Weight, kg, M (Q_1, Q_3) & 27.61 (23.84,33.08) & 27.82 (24.22.33.08) & 26.77 (23.25,33.00) & Z=-1.83 & 0.067 \\ Lymphocytes, M, M (Q_1, Q_3) & 30.00 (23.00,30.00) & 30.00 (30.00,30.00) & 30.00 (20.01,10.00) & Z=-0.38 & <0.001 \\ Neutrophil, kg, Man \pm SD & 90.02 (18.00,27.800) & 197.00 (135.00,283.00) & 192.50 (115.00,269.00) & Z=-1.59 & 0.111 \\ 0.912 & Weight, kg, M (Q_1, Q_3) & 32.00 (107.00,174.00) & 132.00 (107.00,171.00) & 132.50 (107.00,181.00) & Z=-0.48 & <0.592 \\ Platelet, ky, LM, M (Q_1, Q_3) & 30.00 (23.00,30.00) & 30.00 (30.00,30.00) & 6.00 (20.01,10.00) & Z=-0.48 & <0.592 \\ Platelet, ky, LM, M (Q_$	AKI stage, n (%)				$\chi^2 = 84.21$	< 0.001
II370 (44.52)308 (50.57)62 (27.93)III316 (38.03)175 (28.74)141 (63.51)ICU length of stay, day, M (Q,, Q_3)4.25 (2.508.78)4.26 (2.58.9.28)4.16 (2.23.793)Z=1.280.202CCI, M (Q_1, Q_3)6.00 (4.000,00)6.00 (3.00.8.00)8.00 (5.00,11.00)Z=5.69<0.001SAPS-II, M (Q_1, Q_3)6.00 (4.009.00)6.00 (3.00.05.00)53.00 (4.30.6.6.00)Z=10.6.3<0.001SAPS-II, M (Q_1, Q_3)43.00 (33.00.55.00)39.00 (30.00,50.00)53.00 (4.30.6.6.00)Z=10.6.3<0.001GCS, Mean ± SD10.95 ± 2.2011.11 ± 2.2410.52 ± 2.03t=3.41<0.001RDW, %, Mean ± SD15.60 ± 4.7515.16 ± 4.3416.82 ± 5.54t=4.03<0.001GFR, mL/min/1.73m ² , M (Q_1, Q_3)66.81 (37.33,96.98)73.41 (42.16,100.45)51.00 (31.21,86.23)Z=4.84<0.001GPC, % Mean ± SD15.60 ± 4.7515.16 ± 4.3416.82 ± 5.54t=4.03<0.001GPC, % Mean ± SD96.65 ± 4.3696.87 ± 4.1396.05 ± 4.90t=2.210.028NIR, M (Q_1, Q_3)93.61 (5.80,17.40)1.30 (1.20,1.60)1.51 (1.41.02.070)Z=3.97<0.001SpC_2, %, Mean ± SD10.33 (1.20,1.70)1.30 (1.20,1.60)1.55 (1.30,2.20)Z=3.97<0.001NIR, M (Q_1, Q_3)30.00 (68.00,95.30)80.83 (69.35,95.60)7.88 (6.64.59.46.00)Z=1.490.038MI, M (Q_1, Q_3)80.00 (68.00,95.30)80.83 (69.35,95.60)7.95 (1.30.02.20)Z=1.430.067MI, M (Q_1, Q_3		145 (17.45)	126 (20.69)	19 (8.56)	~	
III316 (38.03)175 (28.74)144 (63.51)ICU length of stay, day, M (Q ₁ , Q ₂)4.25 (2.50,8.78)4.26 (2.58,9.28)4.16 (2.23,7.93)Z=1.280.202CCI, M (Q ₁ , Q ₂)2.00 (1.00,4.00)2.00 (1.00,4.00)3.00 (2.00,5.00)Z=5.69<.0.011	11	370 (44.52)	308 (50.57)	62 (27.93)		
ICU length of stay, day, M (Q ₁ , Q ₂)4.25 (2.50,8.78)4.26 (2.58,9.28)4.16 (2.23,793)Z=-1.280.202CCI, M (Q ₁ , Q ₂)2.00 (1.00,4.00)2.00 (1.00,4.00)3.00 (2.00,5.00)Z=5.69<.0.011	111	316 (38.03)	175 (28.74)	141 (63.51)		
$ \begin{array}{c} {\rm CC}, {\rm M} \left({Q_1,Q_3} \right) & 2.00 \left({1.004.00} \right) & 2.00 \left({1.004.00} \right) & 3.00 \left({2.005.00} \right) & {\rm Z} = 5.69 \\ {\rm SOFA}, {\rm M} \left({Q_1,Q_3} \right) & 6.00 \left({4.00,9.00} \right) & 6.00 \left({3.00,8.00} \right) & 8.00 \left({5.00,11.00} \right) & {\rm Z} = 8.03 \\ {\rm C}, {\rm M} \left({Q_1,Q_3} \right) & 43.00 \left({3.00,55.00} \right) & 39.00 \left({3.00,05.00} \right) & 53.00 \left({43.00,66.00} \right) & {\rm Z} = 10.63 \\ {\rm C}, {\rm M} \left({Q_1,Q_3} \right) & 13.57 \pm 2.95 & 13.85 \pm 2.54 & 12.82 \pm 3.76 & t = 3.80 \\ {\rm C}, {\rm M} \left({Q_1,Q_3} \right) & 15.61 \pm 4.22 & 15.18 \pm 2.09 & 16.24 \pm 2.71 & t = 5.31 \\ {\rm C}, {\rm m} E_{\rm M} \left({\rm M} \left({\rm M} \right) {\rm C}_{\rm M} \right) & 15.60 \pm 4.75 & 15.16 \pm 4.34 & 16.82 \pm 5.54 & t = 4.03 \\ {\rm C}, {\rm m} E_{\rm M} \left({\rm M} \left({\rm M} \right) {\rm C}_{\rm M} \right) & 9.66 \pm 1.37.33,96.98 & 73.41 \left({42.16,100.45} \right) & 51.00 \left({31.21,86.23} \right) & {\rm Z} = 4.84 \\ {\rm C} \left({\rm O} 0.11 \\ {\rm SPO_2, \%, {\rm Mean} \pm {\rm SD} & 96.65 \pm 4.36 & 96.87 \pm 4.13 & 96.05 \pm 4.90 & t = 2.21 & 0.028 \\ {\rm NLR, {\rm M} \left({\rm Q}, {\rm Q} \right) & 9.36 \left({5.80,17.40} \right) & 8.73 \left({5.25,15.30} \right) & 11.03 \left({7.18,21.95} \right) & {\rm Z} = 3.97 \\ {\rm C} \left({\rm O} 0.01 \\ {\rm NR, {\rm M} \left({\rm Q}, {\rm Q} \right) & 130 \left({1.20,1.70} \right) & 130 \left({1.20,1.60} \right) & 15.5 \left({1.30,2.20} \right) & {\rm Z} = 5.93 \\ {\rm C} \left({\rm O} 0.01 \\ {\rm NR, {\rm M} \left({\rm Q}, {\rm Q} \right) & 8.00 \left({68.00,95.30} \right) & 80.83 \left({69.35,95.60} \right) & 78.58 \left({66.45,94.60} \right) & {\rm Z} = 1.49 & 0.135 \\ {\rm BM}, {\rm kg/m^2, {\rm M} \left({\rm Q}, {\rm Q} \right) & 27.61 \left({23.84,33.08} \right) & 27.82 \left({24.22,33.08} \right) & 26.77 \left({23.25,33.00} \right) & {\rm Z} = 1.83 & 0.067 \\ {\rm Lymphocytes, \%, {\rm M} \left({\rm Q}, {\rm Q} \right) & 130 \left({0.20,0.717.00} \right) & 130 \left({0.30,0.40} \right) & 7.04 \left({0.01,0.00} \right) & {\rm Z} = 2.856 \\ {\rm C} 0.001 \\ {\rm PNI, {\rm C} \left({\rm M} \right) & 13.00 \left({23.00,0.20,0} \right) & 30.00 \left({30.00,0.00} \right) & 20.20 \left({15.00,0.269.00} \right) & {\rm Z} = -1.59 & 0.111 \\ {\rm O} 1.10 \\ {\rm D} 1.50 \left({12.80,0.278.00} \right) & 197.00 \left({13.50,0.283.00} \right) & 25.71 \left({15.00,0.269.00} \\ {\rm Z} = -1.59 & 0.111 \\ {\rm O} 1.50 \left({2.20,0.278.00} \right) & 197.00 \left({13.50,0.283.00} \right) & 25.0 \\ {\rm C} \left({\rm L} \left$	ICU length of stay, day, M (O_1, O_2)	4.25 (2.50.8.78)	4,26 (2,58,9,28)	4.16 (2.23.7.93)	Z=-1.28	0.202
SOFA, M (Q ₁ , Q ₃)6.00 (400,9.00)6.00 (3.0,8.00)8.00 (5.0,11.00)Z = 8.03< 0.001SAPS-II, M (Q ₁ , Q ₃)43.00 (33.00,55.00)39.00 (30.00,50.00)53.00 (43.00,66.00)Z = 10.63< 0.001	CCI, M (O ₁ , O ₂)	2.00 (1.00.4.00)	2.00 (1.00.4.00)	3.00 (2.00.5.00)	Z=5.69	< 0.001
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	SOFA, M (O ₁ , O ₂)	6.00 (4.00.9.00)	6.00 (3.00.8.00)	8.00 (5.00.11.00)	Z=8.03	< 0.001
GCS, Mean ±SD13.57 ± 2.9513.85 ± 2.5412.82 ± 3.76t = 3.80< 0.001HB, g/dL, Mean ±SD10.95 ± 2.2011.11 ± 2.2410.52 ± 2.03t = 3.41< 0.001	SAPS-II, M (O ₁ , O ₂)	43.00 (33.00.55.00)	39.00 (30.00.50.00)	53.00 (43.00.66.00)	Z=10.63	< 0.001
HB, g/dL, Mean ± SD10.9 ± 2.2011.11 ± 2.2410.52 ± 2.03t = 3.41< 0.001RDW, %, Mean ± SD15.46 ± 2.3215.18 ± 2.0916.24 ± 2.71t = -5.31< 0.001	GCS. Mean + SD	13.57 + 2.95	13.85 + 2.54	12.82 + 3.76	t = 3.80	< 0.001
RDW, %, Mean ±SD15.46 ± 2.3215.18 ± 2.0916.24 ± 2.71t =-5.31< 0.001AG, mEq/L, Mean ±SD15.60 ± 4.7515.16 ± 4.3416.82 ± 5.54t=-4.03< 0.001	HB.g/dL.Mean+SD	10.95 + 2.20	11.11+2.24	10.52 + 2.03	t=3.41	< 0.001
$ \begin{array}{c} \mbox{He} \mbox{Me} \mbox{He} He$	RDW. %. Mean + SD	15.46 + 2.32	15.18+2.09	16.24+2.71	t=-5.31	< 0.001
$ \begin{array}{c} \text{GFR, mL/min/1.73m}^2, M (Q_1, Q_3) & 66.81 (37.33,96.98) & 73.41 (42.16,100.45) & 51.00 (31.21,86.23) & Z=4.84 & 4.001 \\ \text{SpO}_2, \%, \text{Mean} \pm \text{SD} & 96.65 \pm 4.36 & 96.87 \pm 4.13 & 96.05 \pm 4.90 & t=2.21 & 0.028 \\ \text{NLR, M} (Q_1, Q_3) & 9.36 (5.80,17.40) & 8.73 (5.25,15.30) & 11.03 (7.18,21.95) & Z=3.97 & <0.001 \\ \text{PT, seconds, M} (Q_1, Q_3) & 14.90 (13.50,17.70) & 14.60 (13.40,16.90) & 16.15 (14.10,20.70) & Z=5.46 & <0.001 \\ \text{INR, M} (Q_1, Q_3) & 1.30 (1.20,1.70) & 1.30 (1.20,1.60) & 1.55 (1.30,2.20) & Z=5.93 & <0.001 \\ \text{Re, insp/min, Mean} \pm \text{SD} & 20.37 \pm 6.40 & 20.09 \pm 6.41 & 21.14 \pm 6.34 & t=-2.08 & 0.038 \\ \text{Height, cm, Mean} \pm \text{SD} & 169.33 \pm 14.96 & 169.36 \pm 15.88 & 169.24 \pm 12.13 & t=0.11 & 0.912 \\ \text{Weight, kg, M} (Q_1, Q_3) & 80.00 (68.00,95.30) & 80.83 (69.35,95.60) & 78.58 (66.45,94.60) & Z=-1.49 & 0.135 \\ \text{BMI, kg/m}^2, M (Q_1, Q_3) & 27.61 (23.84,33.08) & 27.82 (24.22,33.08) & 26.77 (23.25,33.00) & Z=-1.83 & 0.067 \\ \text{Lymphocytes, \%, M} (Q_1, Q_3) & 8.60 (5.00,13.20) & 9.10 (5.30,14.00) & 7.70 (4.00,11.00) & Z=-4.03 & <0.001 \\ \text{Neutrophil, \%, Mean} \pm \text{SD} & 79.02 \pm 15.78 & 78.83 \pm 14.95 & 79.55 \pm 17.88 & t=-0.54 & 0.592 \\ \text{Platelet, K/uL, M} (Q_1, Q_3) & 132.00 (107.00,174.00) & 132.00 (107.00,171.00) & 132.50 (107.00,181.00) & Z=-28.36 & <0.001 \\ \text{PNL, n} (\%) & \chi^2 = 22.86 & <0.001 \\ \text{PNL, n} (\%) & \chi^2 = 22.86 & <0.001 \\ \text{PNL acts, mg/dL, M} (Q_1, Q_3) & 192 (23.10) & 115 (18.88) & 77 (34.68) \\ \text{PNL acts, mg/dL, M} (Q_1, Q_3) & 192 (23.10) & 115 (18.88) & 77 (34.68) \\ \text{PNL acts, mg/dL, M} (\%) & \chi^2 = 22.86 & <0.001 \\ \text{PNL acts, mg/dL, M} (\%) & \chi^2 = 28.56 & 6.39 (76.90) & 494 (81.12) & 145 (65.32) \\ \end{array}$	AG. mFg/L. Mean + SD	15.60 + 4.75	15.16+4.34	16.82 + 5.54	t=-4.03	< 0.001
$ \begin{array}{c} \text{Carr}(112,113,113,117,116,12,12,37,113,116,12,13,113,111,113,113,113,113,113,113,1$	eGER ml/min/173m ² $M(\Omega_{e}, \Omega_{p})$	66.81 (37.33.96.98)	73 41 (42 16 100 45)	51.00 (31.21.86.23)	7=-4.84	< 0.001
$\begin{aligned} & \text{NLR, M} (Q_1, Q_3) & 9.36 (5.80, 17.40) & 8.73 (5.25, 15.30) & 11.03 (7.18, 21.95) & Z = 3.97 & <0.001 \\ & \text{PT, seconds, M} (Q_1, Q_3) & 14.90 (13.50, 17.70) & 14.60 (13.40, 16.90) & 16.15 (14.10, 20.70) & Z = 5.46 & <0.001 \\ & \text{INR, M} (Q_1, Q_3) & 1.30 (1.20, 1.70) & 1.30 (1.20, 1.60) & 1.55 (1.30, 2.20) & Z = 5.93 & <0.001 \\ & \text{Re, insp/min, Mean \pm SD} & 20.37 \pm 6.40 & 20.09 \pm 6.41 & 21.14 \pm 6.34 & t=-2.08 & 0.038 \\ & \text{Height, cm, Mean \pm SD} & 169.33 \pm 14.96 & 169.36 \pm 15.88 & 169.24 \pm 12.13 & t=0.11 & 0.912 \\ & \text{Weight, kg, M} (Q_1, Q_3) & 80.00 (68.00, 95.30) & 80.83 (69.35, 95.60) & 78.58 (66.45, 94.60) & Z=-1.49 & 0.135 \\ & \text{BMI, kg/m}^2, M (Q_1, Q_3) & 27.61 (23.84, 33.08) & 27.82 (24.22, 33.08) & 26.77 (23.25, 33.00) & Z=-1.83 & 0.067 \\ & \text{Lymphocytes, %, M} (Q_1, Q_3) & 8.60 (5.00, 13.20) & 9.10 (5.30, 14.00) & 7.70 (4.00, 11.00) & Z=-4.03 & <0.001 \\ & \text{Neutrophil, %, Mean \pm SD} & 79.02 \pm 15.78 & 78.83 \pm 14.95 & 79.55 \pm 17.88 & t=-0.54 & 0.592 \\ & \text{Platelet, K/uL, M} (Q_1, Q_3) & 132.00 (107.00, 174.00) & 132.00 (107.00, 171.00) & 132.50 (107.00, 181.00) & Z=-0.48 & 0.633 \\ & \text{Follow-up time, day, M} (Q_1, Q_3) & 30.00 (23.00, 30.00) & 30.00 (30.00, 30.00) & 6.00 (2.00, 13.00) & Z=-28.36 & <0.001 \\ & \text{PNI < 28.5} & 192 (23.10) & 115 (18.88) & 77 (34.68) \\ & \text{PNI > 28.5} & 639 (76.90) & 494 (81.12) & 145 (65.32) \\ & \text{V}^2 = 28.56 & <0.001 \\ & \text{V}^2 $	SnO_2 % Mean + SD	96.65 + 4.36	96.87+4.13	96.05 + 4.90	t=2.21	0.028
PT, seconds, M (Q ₁ , Q ₃) 14.90 (13.50,17.70) 14.60 (13.40,16.90) 16.15 (14.10,20.70) Z = 5.46 < 0.001 INR, M (Q ₁ , Q ₃) 1.30 (1.20,1.70) 1.30 (1.20,1.60) 1.55 (1.30,2.20) Z = 5.93 < 0.001 RR, insp/min, Mean ± SD 20.37 ± 6.40 20.09 ± 6.41 21.14 ± 6.34 t =-2.08 0.038 Height, cm, Mean ± SD 169.33 ± 14.96 169.36 ± 15.88 169.24 ± 12.13 t = 0.11 0.912 Weight, kg, M (Q ₁ , Q ₃) 80.00 (68.00,95.30) 80.83 (69.35,95.60) 78.58 (66.45,94.60) Z =-1.49 0.135 BMI, kg/m ² , M (Q ₁ , Q ₃) 27.61 (23.84,33.08) 27.82 (24.22,33.08) 26.77 (23.25,33.00) Z =-1.83 0.067 Lymphocytes, %, M (Q ₁ , Q ₃) 86.00 (5.00,13.20) 9.10 (5.30,14.00) 7.70 (4.00,11.00) Z =-4.03 < 0.001 Neutrophil, %, Mean ± SD 79.02 ± 15.78 78.83 ± 14.95 79.55 ± 17.88 t =-0.54 0.592 Platelet, K/uL, M (Q ₁ , Q ₃) 196.00 (128.00,278.00) 197.00 (135.00,283.00) 192.50 (115.00,269.00) Z =-1.59 0.111 Glucose, mg/dL, M (Q ₁ , Q ₃) 30.00 (23.00,30.00) 30.00 (30.00,30.00) 6.00 (2.00,13.00) Z =-0.48 0.633 Follow-up time, day, M (Q ₁ , Q ₃) 30.00 (23.00,30.00) 30.00 (30.00,30.00) 6.00 (2.00,13.00) Z =-28.36 < 0.001 PNI < 28.5 192 (23.10) 115 (18.88) 77 (34.68) PNI ≥ 28.5 639 (76.90) 494 (81.12) 145 (65.32) $y^2 = 28.56 < 0.001$	NI B M $(O_1 O_2)$	9 36 (5 80 17 40)	8 73 (5 25 15 30)	11 03 (7 18 21 95)	7=3.97	< 0.001
INR, M (Q1, Q3)1.30 (1.20,1.70)1.30 (1.20,1.60)1.55 (1.30,2.20)Z = 5.93< 0.001RR, insp/min, Mean \pm SD20.37 \pm 6.4020.09 \pm 6.4121.14 \pm 6.34t=-2.080.038Height, cm, Mean \pm SD169.33 \pm 14.96169.36 \pm 15.88169.24 \pm 12.13t=0.110.912Weight, kg, M (Q1, Q3)80.00 (68.00,95.30)80.83 (69.35,95.60)78.58 (66.45,94.60)Z=-1.490.135BMI, kg/m², M (Q1, Q3)27.61 (23.84,33.08)27.82 (24.22,33.08)26.77 (23.25,33.00)Z=-4.03<0.001	PT seconds $M(\Omega_{1}, \Omega_{2})$	14 90 (13 50 17 70)	14 60 (13 40 16 90)	16 15 (14 10 20 70)	Z=5.57	< 0.001
RR, insp/min, Mean \pm SD20.37 \pm 6.4020.09 \pm 6.4121.14 \pm 6.34t=-2.080.038Height, cm, Mean \pm SD169.33 \pm 14.96169.36 \pm 15.88169.24 \pm 12.13t=0.110.912Weight, kg, M (Q ₁ , Q ₃)80.00 (68.00,95.30)80.83 (69.35,95.60)78.58 (66.45,94.60)Z=-1.490.135BMI, kg/m², M (Q ₁ , Q ₃)27.61 (23.84,33.08)27.82 (24.22,33.08)26.77 (23.25,33.00)Z=-1.830.067Lymphocytes, %, M (Q ₁ , Q ₃)8.60 (5.00,13.20)9.10 (5.30,14.00)7.70 (4.00,11.00)Z=-4.03<0.001	(Q_1, Q_3)	1 30 (1 20 1 70)	1 30 (1 20 1 60)	1 55 (1 30 2 20)	Z=5.93	< 0.001
Height cm, Mean ± SD160,31 ± 0.10160,36 ± 15.81169,24 ± 12.13t = 0.110.912Weight, kg, M (Q1, Q3)80.00 (68.00,95.30)80.83 (69.35,95.60)78.58 (66.45,94.60)Z=-1.490.135BMI, kg/m², M (Q1, Q3)27.61 (23.84,33.08)27.82 (24.22,33.08)26.77 (23.25,33.00)Z=-1.830.067Lymphocytes, %, M (Q1, Q3)8.60 (5.00,13.20)9.10 (5.30,14.00)7.70 (4.00,11.00)Z=-4.03<0.001	$\frac{1}{100} \frac{1}{100} \frac{1}$	2037+640	20.09+6.41	21 14 + 6 34	t=-2.08	0.038
Neight, eth, mean 12010000 (10000 1100010000 1100010000 1100010000 1100010000 11000Weight, kg, M (Q1, Q3)80.00 (68.00,95.30)80.83 (69.35,95.60)78.58 (66.45,94.60)Z=-1.490.135BMI, kg/m², M (Q1, Q3)27.61 (23.84,33.08)27.82 (24.22,33.08)26.77 (23.25,33.00)Z=-1.830.067Lymphocytes, %, M (Q1, Q3)8.60 (5.00,13.20)9.10 (5.30,14.00)7.70 (4.00,11.00)Z=-4.03<0.001	Height cm Mean \pm SD	169 33 + 14 96	16936+1588	169 24 + 12 13	t = 0.11	0.050
Notigen, Ng, M (Q1, Q2)Exact (exact, 51.5.7)Exact (05.5.7, 53.60)To as (co.15, 71.60) $Z = 1.15$ CristBMI, kg/m², M (Q1, Q3)27.61 (23.84, 33.08)27.82 (24.22, 33.08)26.77 (23.25, 33.00) $Z = -1.83$ 0.067Lymphocytes, %, M (Q1, Q3)8.60 (5.00, 13.20)9.10 (5.30, 14.00)7.70 (4.00, 11.00) $Z = -4.03$ <0.001	Weight ka $M(\Omega, \Omega_{c})$	80.00 (68.00.95.30)	80.83 (69.35.95.60)	78 58 (66 45 94 60)	7=-1.49	0.135
bin, kg/m , m(q), qg/27.01 (23.01,55.00)27.02 (21.22,55.00)20.77 (23.02,55.00)22.1.02Lymphocytes, %, M (Q1, Q3)8.60 (5.00,13.20)9.10 (5.30,14.00)7.70 (4.00,11.00)Z=-4.03<0.001	$BML ka/m^2 M (\Omega_1, \Omega_2)$	27.61 (23.84.33.08)	27.82 (24.22.33.08)	26 77 (23 25 33 00)	71.83	0.067
Lymphotyles, N, M(Q1, Q3)0.00 (3.00, 13.20)7.10 (4.00, 14.00) $2 = 4.05$ (0.001Neutrophil, %, Mean ± SD79.02 ± 15.7878.83 ± 14.9579.55 ± 17.88t=-0.540.592Platelet, K/uL, M (Q1, Q3)196.00 (128.00,278.00)197.00 (135.00,283.00)192.50 (115.00,269.00)Z=-1.590.111Glucose, mg/dL, M (Q1, Q3)132.00 (107.00,174.00)132.00 (107.00,171.00)132.50 (107.00,181.00)Z=0.480.633Follow-up time, day, M (Q1, Q3)30.00 (23.00,30.00)30.00 (30.00,30.00)6.00 (2.00,13.00)Z=-28.36<0.001	$\sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i$	8 60 (5 00 13 20)	9 10 (5 30 1/ 00)	7 70 (4 00 11 00)	Z= 1.03	< 0.001
Netately init, in, inclusion 73.02 ± 13.00 70.02 ± 13.00 70.00 ± 11.00 70.00 ± 11.00 100 ± 10.00 Platelet, K/uL, M (Q ₁ , Q ₃)196.00 (128.00,278.00)197.00 (135.00,283.00)192.50 (115.00,269.00)Z=-1.590.111Glucose, mg/dL, M (Q ₁ , Q ₃)132.00 (107.00,174.00)132.00 (107.00,171.00)132.50 (107.00,181.00)Z=0.480.633Follow-up time, day, M (Q ₁ , Q ₃)30.00 (23.00,30.00)30.00 (30.00,30.00)6.00 (2.00,13.00)Z=-28.36<0.001	Neutrophil % Mean+SD	79.02 + 15.78	78 83 + 14 95	7955+1788	t=-0.54	0.592
Hatelet, N d2, M (Q1, Q3)130.00 (120.00,270.00)197.00 (150.00,205.00)122.50 (1150.00,205.00)2= 1.550.111Glucose, mg/dL, M (Q1, Q3)132.00 (107.00,174.00)132.00 (107.00,171.00)132.50 (107.00,181.00) $Z = 0.48$ 0.633Follow-up time, day, M (Q1, Q3)30.00 (23.00,30.00)30.00 (30.00,30.00)6.00 (2.00,13.00) $Z = -28.36$ <0.001	Platelet K/ μ M (Ω Ω)	196.00 (128.00.278.00)	197.00 (135.00.283.00)	192 50 (115 00 269 00)	7-159	0.552
Follow-up time, day, M (Q1, Q3) 152.00 (101.00, 174.00) 152.00 (101.00, 174.00) 152.00 (101.00, 174.00) 152.00 (101.00, 174.00) 2 = 0.40 0.005 Follow-up time, day, M (Q1, Q3) 30.00 (23.00, 30.00) 30.00 (30.00, 30.00) 6.00 (2.00, 13.00) Z=-28.36 < 0.001	$G _{UCOSP}$ mg/dL $M(Q_1, Q_3)$	132.00 (107.00.174.00)	132.00 (107.00.171.00)	132.50 (107.00.181.00)	Z= 1.59 Z=0.48	0.111
PNI, n (%) $\chi^2 = 22.30$ $\chi^2 = 22.30$ $\chi^2 = 22.86$ $\chi^2 = 22.86$ PNI < 28.5	Follow-up time day $M(\Omega, \Omega)$	30.00 (23.00.30.00)	30.00 (30.00 30.00)	6.00 (2.00 13.00)	7=-28.36	< 0.000
N_{11} N_{12} <t< td=""><td>PNI n (%)</td><td>50.00 (25.00,50.00)</td><td>55.00 (50.00,50.00)</td><td>0.00 (2.00,10.00)</td><td>$v^2 = 20.30$</td><td>< 0.001</td></t<>	PNI n (%)	50.00 (25.00,50.00)	55.00 (50.00,50.00)	0.00 (2.00,10.00)	$v^2 = 20.30$	< 0.001
PNI ≥ 28.5 639 (76.90) 494 (81.12) 145 (65.32) GNRL n (%) $v^2 = 28.56$ < 0.001	PNI < 28.5	192 (23 10)	115 (18 88)	77 (34.68)	A = 22.00	< 0.00 I
GNRL n (%) $v^2 = 28.56 < 0.001$	PNI > 28.5	639 (76 90)	494 (81 12)	145 (65 32)		
$\mathbf{r} = \mathbf{r} \mathbf{r} \mathbf{u}$	GNBL n (%)	0.55 (70.50)	191 (01.12)	1 10 (00.02)	$v^2 = 28.56$	< 0.001

Table 1 (continued)

Variables	Total (n=831)	Survival (n=609)	Mortality (n=222)	Statistics	Р
GNRI < 83.25	353 (42.48)	225 (36.95)	128 (57.66)		
GNRI≥83.25	478 (57.52)	384 (63.05)	94 (42.34)		

AKI: acute kidney injury, ICU: intensive care unit, CCI: Charlson comorbidity index, SOFA: sequential organ failure assessment, SAPS-II: simplified acute physiology score II, GCS: glasgow coma scale, HB: hemoglobin, RDW: red blood cell distribution width, AG: anion gap, eGFR: esti mated glomerularfiltrationrate, SpO₂: oxygen saturation, NLR: neutrophil lymphocyte ratio, PT: prothrombin time, INR: international normalized ratio, RR: respiratory rate, BMI: body mass index, PNI: prognostic nutritional index, GNRI: geriatric nutritional risk index

t: t test, χ^2 : chi-square test, Z: Whitney U rank sum test

Table 2 Correlation of PNI and GNRI and severity of AKI

Variables	eGFR	eGFR		AKI stage		SOFA		SAPS-II	
	r	Р	r _s	Р	r _s	Р	r _s	Р	
PNI	0.076	0.028	-0.198	< 0.001	-0.310	< 0.001	-0.276	< 0.001	
GNPI	0.063	0.069	-0.200	< 0.001	-0.320	< 0.001	-0.300	< 0.001	

PNI: prognostic nutritional index, GNRI: geriatric nutritional risk index, AKI: acute kidney injury, eGFR: esti mated glomerularfiltrationrate, SOFA: sequential organ failure assessment, SAPS-II: simplified acute physiology score II.

Table 3	Associatio	n between PN	II and GNRI	and 30-day	[,] mortality	' and in age,	SOFA, and S.	APS-II subgrc	oups

Subgroups	Variables	Model 1		Model 2		Model 3	
		h (95% Cl)	Р	HR (95% CI)	Р	HR (95% CI)	Р
	PNI ¹	0.51 (0.39–0.68)	< 0.001	0.48 (0.37–0.64)	< 0.001	0.71 (0.51–0.98)	0.036
	GNRI ²	0.49 (0.38-0.64)	< 0.001	0.47 (0.36-0.61)	< 0.001	0.63 (0.47-0.86)	0.003
Age < 65	PNI ¹	0.54 (0.35-0.83)	0.005	0.49 (0.31-0.75)	0.001	1.14 (0.67–1.96)	0.622
	GNRI ²	0.47 (0.31-0.72)	< 0.001	0.43 (0.28-0.66)	< 0.001	1.07 (0.65–1.75)	0.793
Age≥65	PNI ¹	0.50 (0.35-0.71)	< 0.001	0.48 (0.34-0.69)	< 0.001	0.54 (0.35-0.82)	0.004
	GNRI ²	0.50 (0.35-0.70)	< 0.001	0.48 (0.34-0.68)	< 0.001	0.51 (0.34–0.76)	< 0.001
SOFA < 6	PNI ¹	0.38 (0.21-0.67)	< 0.001	0.36 (0.20-0.65)	< 0.001	0.38 (0.18-0.81)	0.012
	GNRI ²	0.57 (0.34–0.96)	0.035	0.52 (0.31-0.89)	0.016	0.57 (0.28-1.14)	0.110
SOFA≥6	PNI ¹	0.69 (0.50-0.94)	0.021	0.67 (0.49-0.92)	0.013	0.80 (0.55-1.15)	0.223
	GNRI ²	0.57 (0.42-0.78)	< 0.001	0.56 (0.41-0.77)	< 0.001	0.65 (0.46-0.93)	0.018
SAPS-II < 43	PNI ¹	0.30 (0.17-0.53)	< 0.001	0.25 (0.14-0.45)	< 0.001	0.22 (0.11-0.46)	< 0.001
	GNRI ²	0.62 (0.36-1.08)	0.090	0.52 (0.29-0.90)	0.021	0.62 (0.32-1.22)	0.169
SAPS-II≥43	PNI ¹	0.79 (0.58–1.09)	0.148	0.81 (0.59–1.13)	0.212	0.89 (0.62-1.28)	0.521
	GNRI ²	0.61 (0.45-0.84)	0.002	0.63 (0.46-0.87)	0.005	0.63 (0.44-0.88)	0.008

PNI: prognostic nutritional index, GNRI: geriatric nutritional risk index, SOFA: sequential organ failure assessment, SAPS-II: simplified acute physiology score II, HR: hazard ratio, CI: confidence interval

1: PNI≥28.5

2: GNRI≥83.25

Model 1 was the crude model;

Model 2 adjusted for age, gender, and race;

Model 3 adjusted for age, gender, and race mechanical ventilation use, vasopressors use, AKI stage, ICU length of stay, CCI, SOFA, SAPS-II, HB, RDW, AG, eGFR, SpO2, NLR, PT, GCS, INR, and RR.

Notes: the variables to classify subgroup were not adjusted in its subgroup

the nutritional, immunity statuses and mortality of AKI patients in theory.

The predictive value of GNRI on AKI prognosis has also not been reported. Research by Seoudy et al. [28] indicated that low GNRI was related to an increased risk of all-cause mortality in patients received transcatheter aortic valve replacement (TAVR). A study on patients with acute respiratory distress syndrome (ARDS) showed that the GNRI on admission was linked to 30-day mortality, and may be a useful index to assess the mortality [29]. The current study has found that in AKI patients, high GNRI was associated with low risk of 30-day mortality. Serum albumin and BMI are two important components for the calculation of GNRI. Lacking of protein and amino acid supply in chronic malnutrition cases results in the formation of albumin reduction, and serum albumin concentration is reduced [28]. However, BMI has not been found to be associated with the mortality in patients with AKI in this research. Dietary sufficient/ supplemented protein intake might influence serum albumin accompanied by weight gain, then the BMI is elevated, and finally the GNRI increases. Therefore, the



Fig. 2 KM curve of the of the different PNI levels in AKI patients

mechanism of association between high GNRI and low risk of 30-mortality in AKI is needed further exploration.

In patients who aged≥65 years old, high PNI and GNRI were both associated with low risk of 30-day mortality. In our study, patients who suffered from AKI were mostly with an old age (average aged 64.61 years old), in which≥65 years old accounted for 51.87%. Previous studies demonstrated that malnutrition in older patients is common [30, 31]. The results of a research on comparing the predictive values of different nutritional risk assessment tools on perioperative clinical outcomes showed that the elderly patients undergoing elective spinal surgery, those who were diagnosed as malnutrition according to the PNI and GNRI, were at an increased risk for adverse events after surgery, and the GNRI had a better predictive power than the PNI [32]. Acarbaş et al. [33] found that older age and PNI<47.7 were predictors of perioperative adverse events. In our opinion, GNRI and PNI may be potential predictors in AKI patients who aged \geq 65 years old.

Mild AKI patients with SOFA score<6 or SAPS-II score<43 who had high PNI were seemed to have low risk of 30-day mortality. Differently, these negative association between GNRI and 30-day mortality were found in patients with severe AKI (SOFA score≥6 and SAPS-II score \geq 43). Malnutrition is prevalent in patients with AKI and is related to an increased in-hospital length of stay and all-cause mortality [34]. Critical illness is a hypermetabolic state, and consequently, patients with severe AKI are found to have an accelerated metabolic rate compared with patients with normal renal function [35]. The Society of Critical Care Medicine (SCCM) recommend using the Nutrition Risk in Critically III (NUTRIC) and Nutrition Risk Screening 2002 (NRS-2002) screening tools to assess nutrition risk in ICU patients [36]. The NUTRIC incorporates multiple variables, including age, number of comorbidities, SOFA scores, and number of days at hospital prior to admission in the ICU [36]. Patients with a higher NUTRIC scores are considered to be a strong positive association with higher 6-month mortality [37], but it is not frequently performed because



Fig. 3 KM curve of the of the different GNRI levels in AKI patients

 Table 4
 Predictive performance of PNI and GNRI on 30-day mortality in AKI patients

C-index			
0.807			
0.806			

PNI: prognostic nutritional index, GNRI: geriatric nutritional risk index, AKI: acute kidney injury

of its high cost. Our results similarly found PNI and GNRI both had potential predictive values in AKI inhospital mortality, but it may be affected by the age and severity assessment tools. Given that malnutrition has a strong association with in-hospital mortality, optimizing nutrition status is a key target for optimizing clinical care. How to select accurate nutritional status evaluation indicators in patients with different clinical conditions still needs further exploration.

This study explored the relationships between PNI and GNRI and 30-day mortality in patients with AKI, which may partly provide some references on potential predictors exploration in high-risk AKI patients. There are some limitations in the current research. The missing data were deleted, which may lead to overestimation of the outcome event. However, the results of sensitive analysis showed no significant difference of characteristics of participants before and after deletion of missing data. As a simple-center retrospective cohort study, selection bias is inevitable. It is difficult to adjust for all confounders such as the unknown intervention out of the ICU. Besides, the MIMIC-III database is short of other immunonutritional scores such as the Controlling Nutritional Status (CONUT) which could not be added to the predictive value comparison.

Conclusion

PNI and GNRI may be potential predictors of 30-day mortality in patients with AKI. Further studies are needed to explore the exact association of PNI and GNRI with short-term mortality in patients with different conditions of AKI.

Abbreviations

AKI PNI GNRI	Acute kidney injury prognostic nutritional index geriatric nutritional risk index
MIMIC-III	Medical Information Mart for Intensive Care III
ICU	intensive care unit
SpO ₂	oxygen saturation
NLR	neutrophil lymphocyte ratio
PT	prothrombin time
KDIGO	Kidney Disease Improving Global Outcomes
Scr	serum creatinine
CCI	Charlson comorbidity index
SOFA	Sequential Organ Failure Assessment
SAPS-II	Simplified Acute Physiology Score II
GCS	Glasgow Coma Scale
HB	hemoglobin
RDW	red blood cell distribution width
AG	anion gap
eGFR	esti mated glomerularfiltrationrate
INR	international normalized ratio
RR	respiratory rate
BMI	body mass index
HRs	hazard ratios
Cls	confidence intervals
KM	Kaplan-Meierwith

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12882-023-03329-5.

Supplementary Material 1

Acknowledgements

Not applicable.

Authors' contributions

TG and XY designed the study. TG wrote the manuscript. TG and XY collected, analyzed, and interpreted the data. XY critically reviewed, edited, and approved the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Data Availability

The datasets generated and/or analyzed during the current study are available in the MIMIC-III database, https://mimic.physionet.org/iii/.

Declarations

Ethics approval and consent to participate

The requirement of ethical approval for this was waived by the Institutional Review Board of Qi Lu Hospital of Shandong University, because the data was accessed from MIMIC-III database (a publicly available database). The need for written informed consent was waived by the Institutional Review Board of Qi Lu Hospital of Shandong University due to retrospective nature of the study. All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 28 April 2023 / Accepted: 10 September 2023 Published online: 06 October 2023

References

- 1. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in Hospitalized patients with COVID-19. J Am Soc Nephrol. 2021;32:151–60.
- Xiao Z, Huang Q, Yang Y, Liu M, Chen Q, Huang J, et al. Emerging early diagnostic methods for acute kidney injury. Theranostics. 2022;12:2963–86.
- Quiroga B, Sanz Sainz M, Santos Sanchez-Rey B, Munoz Ramos P, Ortiz A, Ruano P. Persistent kidney dysfunction after acute kidney injury predicts short-term outpatient mortality. Intern Med J. 2022;52:834–40.
- Fiaccadori E, Sabatino A, Barazzoni R, Carrero JJ, Cupisti A, De Waele E, et al. ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clin Nutr. 2021;40:1644–68.
- Li C, Xu L, Guan C, Zhao L, Luo C, Zhou B, et al. Malnutrition screening and acute kidney injury in hospitalised patients: a retrospective study over a 5-year period from China. Br J Nutr. 2020;123:337–46.
- Efe SC, Karagoz A, Dogan C, Bayram Z, Cakmak EO, Kalkan S, et al. Prognostic significance of malnutrition scores in elderly patients for the prediction of contrast-induced acute kidney injury. Int J Clin Pract. 2021;75:e14274.
- Berbel MN, Goes CR, Balbi AL, Ponce D. Nutritional parameters are associated with mortality in acute kidney injury. Clin (Sao Paulo). 2014;69:476–82.
- Han M, Lee HW, Lee HC, Kim HJ, Seong EY, Song SH. Impact of nutritional index on contrast-associated acute kidney injury and mortality after percutaneous coronary intervention. Sci Rep. 2021;11:7123.
- Hua X, Long ZQ, Huang X, Deng JP, He ZY, Guo L, et al. The value of Prognostic Nutritional Index (PNI) in Predicting Survival and Guiding Radiotherapy of patients with T1-2N1 breast Cancer. Front Oncol. 2019;9:1562.
- Wada H, Dohi T, Miyauchi K, Jun S, Endo H, Doi S, et al. Relationship between the prognostic nutritional index and long-term clinical outcomes in patients with stable coronary artery disease. J Cardiol. 2018;72:155–61.
- Zhang H, Tao Y, Wang Z, Lu J. Evaluation of nutritional status and prognostic impact assessed by the prognostic nutritional index in children with chronic kidney disease. Med (Baltim). 2019;98:e16713.
- 12. Moon SW, Lee EH, Choi JS, Leem AY, Lee SH, Lee SH, et al. Impact of prognostic nutritional index on outcomes in patients with Mycobacterium avium complex pulmonary disease. PLoS ONE. 2020;15:e0232714.
- Liao CK, Chern YJ, Hsu YJ, Lin YC, Yu YL, Chiang JM et al. The clinical utility of the Geriatric Nutritional Risk Index in Predicting Postoperative Complications and Long-Term Survival in Elderly patients with colorectal Cancer after curative surgery. Cancers (Basel). 2021; 13.
- Abd-El-Gawad WM, Abou-Hashem RM, El Maraghy MO, Amin GE. The validity of Geriatric Nutrition Risk Index: simple tool for prediction of nutritionalrelated complication of hospitalized elderly patients. Comparison with Mini Nutritional Assessment. Clin Nutr. 2014;33:1108–16.
- Cereda E, Klersy C, Pedrolli C, Cameletti B, Bonardi C, Quarleri L, et al. The Geriatric Nutritional Risk Index predicts hospital length of stay and in-hospital weight loss in elderly patients. Clin Nutr. 2015;34:74–8.
- Fan T, Wang H, Wang J, Wang W, Guan H, Zhang C. Nomogram to predict the risk of acute kidney injury in patients with diabetic ketoacidosis: an analysis of the MIMIC-III database. BMC Endocr Disord. 2021;21:37.
- Cadwell JB, Afonso AM, Shahrokni A. Prognostic nutritional index (PNI), independent of frailty is associated with six-month postoperative mortality. J Geriatr Oncol. 2020;11:880–4.
- Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.
- Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82:777–83.
- Zhao Y, Lin T, Hou L, Zhang M, Peng X, Xie D, et al. Association between Geriatric Nutritional Risk Index and Frailty in older hospitalized patients. Clin Interv Aging. 2021;16:1241–9.
- 21. Shimoyama Y, Umegaki O, Kadono N, Minami T. Presepsin and prognostic nutritional index are predictors of septic acute kidney injury, renal replacement therapy initiation in sepsis patients, and prognosis in septic acute kidney injury patients: a pilot study. BMC Nephrol. 2021;22:219.
- Hu Y, Cao Q, Wang H, Yang Y, Xiong Y, Li X, et al. Prognostic nutritional index predicts acute kidney injury and mortality of patients in the coronary care unit. Exp Ther Med. 2021;21:123.
- 23. Sertdemir AL, Icli A, Aribas A, Tatar S, Akilli NB, Alsancak Y, et al. Prognostic nutritional index and the risk of acute kidney injury in patients with acute coronary syndrome. Rev Assoc Med Bras (1992). 2021;67:1124–9.

- Kurtul A, Gok M, Esenboga K. Prognostic Nutritional Index predicts Contrast-Associated Acute kidney Injury in Patients with ST-Segment Elevation myocardial infarction. Acta Cardiol Sin. 2021;37:496–503.
- Li L, Dai L, Wang X, Wang Y, Zhou L, Chen M, et al. Predictive value of the C-reactive protein-to-prealbumin ratio in medical ICU patients. Biomark Med. 2017;11:329–37.
- Joles JA, Willekes-Koolschijn N, Koomans HA. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int. 1997;52:761–70.
- Widmer A, Linka AZ, Attenhofer Jost CH, Buergi B, Brunner-La Rocca HP, Salomon F, et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99:25–31.
- Seoudy H, Al-Kassou B, Shamekhi J, Sugiura A, Frank J, Saad M, et al. Frailty in patients undergoing transcatheter aortic valve replacement: prognostic value of the Geriatric Nutritional Risk Index. J Cachexia Sarcopenia Muscle. 2021;12:577–85.
- 29. Yoo JW, Ju S, Lee SJ, Cho YJ, Lee JD, Kim HC. Geriatric nutritional risk index is associated with 30-day mortality in patients with acute respiratory distress syndrome. Med (Baltim). 2020;99:e20671.
- van Wissen J, van Stijn MF, Doodeman HJ, Houdijk AP. Mini Nutritional Assessment and Mortality after hip fracture surgery in the Elderly. J Nutr Health Aging. 2016;20:964–8.
- Geurden B, Franck E, Weyler J, Ysebaert D. The risk of Malnutrition in Community-Living Elderly on admission to hospital for major surgery. Acta Chir Belg. 2015;115:341–7.
- Acarbas A, Bas NS. Which Objective Nutritional Index is better for the prediction of adverse medical events in Elderly Patients undergoing spinal surgery? World Neurosurg. 2021;146:e106–e11.

- Acarbas A. A novel prognostic marker in patients undergoing spinal surgery: Prognostic Nutritional Index. J Neurol Surg A Cent Eur Neurosurg. 2019;80:470–4.
- Fiaccadori E, Maggiore U, Cabassi A, Morabito S, Castellano G, Regolisti G. Nutritional evaluation and management of AKI patients. J Ren Nutr. 2013;23:255–8.
- Schneeweiss B, Graninger W, Stockenhuber F, Druml W, Ferenci P, Eichinger S, et al. Energy metabolism in acute and chronic renal failure. Am J Clin Nutr. 1990;52:596–601.
- McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the adult critically ill patient: society of critical Care Medicine (SCCM) and american Society for Parenteral and Enteral Nutrition (A.S.P.E.N). JPEN J Parenter Enteral Nutr. 2016;40:159–211.
- Rahman A, Hasan RM, Agarwala R, Martin C, Day AG, Heyland DK. Identifying critically-ill patients who will benefit most from nutritional therapy: further validation of the modified NUTRIC nutritional risk assessment tool. Clin Nutr. 2016;35:158–62.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.